Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA Personalized Tumor Vaccine + Sintilimab in Liver Cancer
NCT05761717Phase 1Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Apr 2023
- Primary completion
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of SW-H-201 in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Recurrence-Free Survival at 1 year and Overall Survival at 1 year. Status: unknown.
02
Drugs
SW-H-201
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05761717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05761717.